Patent Royalty Payments Sample Clauses

Patent Royalty Payments. On a […***…], GSK shall pay Zymeworks a royalty (the “Royalty”) on Net Sales of each Product at the rates set forth below: Annual Net Sales on a Product-by-Product basis Royalty Rate (as a percentage of Net Sales) $[…***…] up to $[…***…] […***…] % Annual Net Sales on a Product-by-Product basis Royalty Rate (as a percentage of Net Sales) Above $[…***…] to $[…***…] […***…] % Above $[…***…] […***…] %
Sample 1Sample 2See All (5)
AutoNDA by SimpleDocs
Patent Royalty Payments. Lilly shall pay Zymeworks a royalty (each such royalty payment, a “Royalty”) on Net Sales of each Product at the rates set forth below: Annual Worldwide Net Sales on a Product-by-Product basis Royalty Rate USD $[…***…]to USD $[…***…] […***…]% Above USD $[…***…]to USD $[…***…] […***…]% Above USD $[…***…] […***…]%
Sample 1Sample 2Sample 3
Patent Royalty Payments. Merck shall pay Zymeworks a royalty (each such royalty payment under this Section 6.3.1 and Section 6.3.2 constituting a “Royalty”) on Net Sales of each Product in each country in the Territory where, were it not for a license granted to Merck under Article 2, the sale of such Product in a country would infringe a Valid Patent Claim, at the following rates (which are a percentage of Net Sales). Calendar Year worldwide Net Sales of Each Product Royalty Rate USD $[…***…] to USD $[…***…] […***… ]% Above USD $[…***…] to USD $[…***…] […***… ]% Above USD $[…***…] […***… ]%
Sample 1Sample 2
Patent Royalty Payments. Xxxxx shall pay Zymeworks a royalty (each such royalty payment, a “Royalty”) on Net Sales of each Product at the rates set forth below: Annual Worldwide Net Sales on a Product-by-Product basis Royalty Rate USD $[ *** ] to USD $[ *** ] [ *** ]% Above USD $[ *** ]to USD $[ *** ] [ *** ]% Above USD $[ *** ] [ *** ]%
Sample 1Sample 2
Patent Royalty Payments. Celgene shall pay Zymeworks a royalty (each such royalty payment, a “Royalty”) on Net Sales of each Product (with Royalties generated by the US paid by Celgene Corp. and Royalties generated outside of the US paid by Celgene Alpine) at the rates set forth below: Royalty Tier Annual Net Sales on a Product-by-Product basis Royalty Rate A USD $[…***…] to USD $[…***…] of Net Sales of the particular Product […***…] % B Above USD $[…***…] to USD $[…***…] of Net Sales of the particular Product […***…] % C Above USD $[…***…] of Net Sales of the particular Product […***…] %
Sample 1Sample 2
Patent Royalty Payments. Archon will pay Patent Royalties to Xxxxxx on a quarterly basis. More particularly, Archon will make Patent Royalty payments within thirty (30) days after the close of each calendar quarter, namely on or before January 30, April 30, July 30, and October 30 of the applicable year. Such payments will be for all Patent Royalties accrued for the immediately preceding quarter. Unless otherwise instructed by Xxxxxx, these payments will be made by check directly to Xxxxxx at the following address: Xxxxx X. Xxxxxx 0000 X. Xxxxxx Pines Las Vegas, NV 89146. Simultaneously with the payment of Patent Royalties, Archon will provide a Patent Royalty report quantifying the Patent Royalty amounts accrued during the previous quarter explaining the basis for such payments. If no Patent Royalties Fees are due to Xxxxxx for a particular quarter, Archon will provide a report to Xxxxxx so stating.
Sample 1

Related to Patent Royalty Payments

  • Royalty Payments (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

  • Royalty Payment For all leased substances that are sold during a particular month, Lessee shall pay royalties to Lessor on or before the end of the next succeeding month. Royalty payments shall be accompanied by a verified statement, in a form approved by Lessor, stating the amount of leased substances sold, the gross proceeds accruing to Lessee, and any other information reasonably required by Lessor to verify production and disposition of the leased substances or leased substances products. Delinquent royalties may be subject to late fees and penalties in accordance with Lessor’s Rules.

  • Royalties 1. Royalties arising in a Contracting State and paid to a resident of the other Contracting State may be taxed in that other State.

  • Running Royalties Company shall pay to JHU a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) sold, and for each LICENSED SERVICE(S) provided, by Company or AFFILIATED COMPANIES, based on NET SALES and NET SERVICE REVENUES for the term of this Agreement. Such payments shall be made quarterly. All non-US taxes related to LICENSED PRODUCT(S) or LICENSED SERVICE(S) sold under this Agreement shall be paid by Company and shall not be deducted from royalty or other payments due to JHU. In order to insure JHU the full royalty payments contemplated hereunder, Company agrees that in the event any LICENSED PRODUCT(S) shall be sold to an AFFILIATED COMPANY or SUBLICENSEE(S) or to a corporation, firm or association with which Company shall have any agreement, understanding or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances) the royalties to be paid hereunder for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the net selling price (per NET SALES) at which the purchaser of LICENSED PRODUCT(S) resells such product to the end user, 2) the NET SERVICE REVENUES received from using the LICENSED PRODUCT(S) in providing a service, or 3) the net selling price (per NET SALES) of LICENSED PRODUCT(S) paid by the purchaser. No multiple royalties shall be due or payable because any LICENSED PRODUCT(S) or LICENSED SERVICE(S) is covered by more than one claim of the PATENT RIGHTS or by claims of both the PATENT RIGHTS under this Agreement and “PATENT RIGHTS” under any other license agreement between Company and JHU. The royalty shall not be cumulative based on the number of patents or claims covering a product or service, but rather shall be capped at the rate set forth in Exhibit A.

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Earned Royalty In addition to the annual license maintenance fee, ***** will pay Stanford earned royalties (Y%) on Net Sales as follows:

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Royalty Fees In further consideration of the distribution rights and related rights granted by Shengqu to the Licensees hereunder, the Licensees shall pay to Shengqu a royalty fee equal to 35% of revenues on a monthly basis.

  • Third Party Royalties Each party shall be responsible for all of its own costs of commercializing Products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sublicensees.

  • Sublicense Revenue In the event Licensee or an Affiliate of Licensee sublicenses under Section 2.2, Licensee shall pay CareFusion **THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION.** of any Sublicense Revenues resulting from sublicense agreements executed by Licensee.

Time is Money Join Law Insider Premium to draft better contracts faster.